期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

儿童血友病A低剂量预防治疗的疗效观察 被引量：9

Efficacy of low-dose preventive treatment on hemophilia A in children
原文传递
导出
摘要 目的观察儿童血友病A低剂量预防治疗的效果。方法应用重组人凝血因子Ⅷ对24例中、重型血友病A进行预防治疗,剂量为10～15U/(kg·次),每周2次静脉注射。3个月为1个疗程,连续2个疗程。观察预防治疗前后患儿关节出血、生活自理能力、抑制物产生及治疗费用。结果预防治疗后,中、重型血友病A患儿的关节出血频率由治疗前的2.88次/半年、8.4次/半年降为0.11次/半年和1次/半年;生活自理能力明显提高;治疗6个月后,Ⅷ因子抑制物测定结果为阴性;相对于按需治疗,治疗费用并没有明显增加。结论儿童血友病A低剂量预防治疗安全、有效,且没有明显增加治疗费用。 Objective To evaluate the effect of low dose prophylaxis on heamophilic children. Methods Twenty-four Children with moderate and severe haemophilia were followed for a 6-month observation period followed by a 6 -month low dose prophylaxis （rhFVIII 10 μ/kg, twice weekly）. Results The number of joint hemorrhage decreased, school attendance improved during the observation period. No inhibitor was found in all cases. The medical cost was not increased compared to the on-demand therapy. Conclusion Low dose prophylaxis is safe and effective for haemophia A in children.
作者 胡群 秦秀丽 刘爱国 刘双又 张柳清 叶天惠
机构地区 华中科技大学同济医学院附属同济医院儿科
出处 《北京医学》 CAS 2013年第4期257-259,共3页 Beijing Medical Journal
关键词 儿童 血友病A 治疗 Children Haemophia A Treatment
分类号 R725.5 [医药卫生—儿科]
  • 相关文献

参考文献6

  • 1郭晔,张磊,竺晓凡,杨仁池.儿童血友病429例临床回顾分析[J].中国实用儿科杂志,2006,21(4):292-295. 被引量：37
  • 2Steen CK, Hojgard S, Glomstein A, et al. On demand vs. prophylactic trentment for severe hemophilia in Norway and Sweden. Haemophila,2003,9:555-66.
  • 3儿童血友病诊疗建议[J].中华儿科杂志,2011,49(3):193-195. 被引量：31
  • 4Nilsson IM, Berntorp E, Lofqvist T, et al. Twenty-five years expe- rience of prophylactic treatment in severe heamophilia A and B. J Inst Med,1992,232:25-32.
  • 5Feldman BM, Pai M, Ribard GE, et al. Tailored prophylaxis in severe hemophilia A. J Thromb Haemost,2006,4:1228-1236.
  • 6吴润晖.血友病的预防治疗[J].血栓与止血学,2010,16(4):183-186. 被引量：8

二级参考文献10

  • 1郭晔,张磊,竺晓凡,杨仁池.儿童血友病429例临床回顾分析[J].中国实用儿科杂志,2006,21(4):292-295. 被引量：37
  • 2邓家栋 杨崇礼 杨天楹 等.临床血液学[M].上海：上海科学技术出版社,2001.1085-1090.
  • 3Venkateswaran L,Wilimas JA,Jones DJ,et al.Mild hemophilia in children:prevalence,complications and treatment[J].J Pediatr Haematol/Oncol,1998,20(1):32-35.
  • 4Lijung R.Can haemophiliacs arthropathy be prevented?[J].Br J Haematol,1998,101 (2):215-219.
  • 5Aledort LM,Haschmeyer RH,Pettersson H.The Orthopaedic Outcome Study Group.A longitudinal study of orthopaedics outcomes for severe factor Ⅷ deficient hemophiliacs[J].J Intern Med Med,1994,236(4):391-399.
  • 6Telfer P,Sabin C,Devereux H,Scott F,Dusheiko G,Lee C.The progression of HCV-associated liver disease in a cohort of haemophilic patients[J].Br J Haematol,1994,87 (3):555-561.
  • 7Koumbraelis E,Rosendaal FR,Gialeraki A,et al.Epidemiology of haemophilia in Greece:an overview[J].Thromb Haemost,1994,72(6):808-813.
  • 8Briet E,Rosendaal FR,Kreuz W,et al.High titer inhibitors in severe hemophilia A:a meta-analysis based on eight long-term follow-up studies concerning inhibitiors associated with crude or intermediate purity factor products[J].Thromb Haemost,1994,72(1):162-164.
  • 9吴润晖,吴心怡,冯涛,马洁,吴敏媛.儿童血友病病人临床资料及现状分析[J].血栓与止血学,2008,14(3):116-120. 被引量：45
  • 10丁培芳,张志传,张心声,颜新,申法奎.血友病甲患者抗-HCV和抗-HIV阳性率调查分析[J].中国输血杂志,2002,15(3):212-213. 被引量：10

共引文献67

同被引文献86

  • 1郭晔,张磊,竺晓凡,杨仁池.儿童血友病429例临床回顾分析[J].中国实用儿科杂志,2006,21(4):292-295. 被引量：37
  • 2Gouw S C, van den Berg HM. The muhifactorial etiology of inhibitor development in hemophilia: genetics and environment [J]. Semin Thmmb Hemost, 2009, 35(2) : 723-734.
  • 3Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the managementof hemophilia [ J ]. Haemophilia, 2013, 19(1): el-e47.
  • 4Wang XF, Zhao YQ, Yang RC, et al. The prevalence of factor W inhibitors and genetic aspects of inhibitor development in Chinese patients with haemophilia A [ J ]. Haemophilia, 2010, 16 (4) : 632-639.
  • 5Chambost H. Assessing risk factors: prevention of inhibitors in haemophilia[ J]. Haemophilia, 2010, 16(Suppl 2) : 10-15.
  • 6Viel KR, Ameri A, Abshire TC, et al. Inhibitors of factor V in black patients with hemophilia[ J]. N Engl J Med, 2009, 360 (16) : 1618-1627.
  • 7Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia [ J ]. Haemophilia, 2013, 19( 1 ) : el-e47.
  • 8Goudemand J, Rothschild C, Demlguel V, et al. Influence of the type of factor VW concentrate on the incidence of facto r V inhibitors in previously untreated patients with severe hemophilia A[J]. Blood, 2006, 107(1):46-51.
  • 9Hay CR, Baqlin TP, Collins PW, et al. The diagnosis and managent of factor V and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organiation [ J ]. Br J Haematol, 2006, 133(6): 591-605.
  • 10Astev, aark J, Altisent C, Batoroa A, et al. Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report [ J ]. Haemophilia, 2010, 16(5) : 747-766.

引证文献9

二级引证文献21

北京医学
2013年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部